肝细胞癌立体定向射频消融:移植肝组织病理学研究
本回顾性研究纳入2009至2018年97例接受立体定向射频消融桥接治疗后肝移植的肝细胞癌患者,共195个病灶,利用移植肝组织病理评估疗效。中位随访间隔6.8个月,可评估的188个病灶中完全病理应答率为97.3%,病灶≥3 cm者完全肿瘤细胞死亡率为96.2%,残留肿瘤与肿瘤大小无关(P=0.5)。
要点
- 立体定向射频消融治疗肝细胞癌的完全病理应答率达97.3%(183/188个病灶)。
- 病灶≥3 cm者完全肿瘤细胞死亡率为96.2%(50/52个病灶)。
- 残留肿瘤与肿瘤大小不相关(P=0.5)。
核心结论
- 三维导航多探针射频消融联合术中图像融合是治疗肝细胞癌的有效微创疗法,即使肿瘤大于3 cm也无需联合其他治疗。
- 研究结果似乎支持立体定向方法所需的额外努力。
研究设计与样本
- 回顾性研究,2009至2018年97例肝细胞癌患者(84男,13女;中位年龄60岁,范围1-71岁)接受立体定向射频消融桥接治疗后肝移植,共治疗195个病灶。
- 首次立体定向射频消融至移植的中位间隔为6.8个月(范围0-71个月)。
- 通过移植肝组织H&E和TUNEL染色评估188个病灶(来自96例患者)的残留活组织率。
主要发现
- 中位治疗肿瘤数目为1个(范围1-8),中位大小为2.5 cm(范围1-8)。
- 完全影像学应答在186/188个结节(98.9%)和94/96例患者(97.9%)中达到。
- 完全病理学应答在移植肝标本中为183/188个结节(97.3%)和91/96例患者(94.8%)。
- 病灶≥3 cm者完全肿瘤细胞死亡率为50/52个结节(96.2%)。
- 残留肿瘤与肿瘤大小不相关(P=0.5)。
关键数值与推荐
- 完全影像学应答:结节水平98.9%(186/188),患者水平97.9%(94/96)。
- 完全病理学应答:结节水平97.3%(183/188),患者水平94.8%(91/96)。
- 病灶≥3 cm完全肿瘤细胞死亡率96.2%(50/52)。
- 残留肿瘤与肿瘤大小相关性检验P=0.5。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This retrospective study was performed to evaluate the efficacy of three-dimensional (3D)-navigated multiprobe radiofrequency ablation (RFA) with intraprocedural image fusion for treatment of hepatocellular carcinoma (HCC) by histopathological examination. From 2009 to 2018, 97 patients (84 men, 13 women; median age, 60 years; range, 1-71) were transplanted after bridging therapy of 195 HCCs by stereotactic RFA (SRFA). The median interval between the first SRFA and transplantation was 6.8 months (range, 0-71). The rate of residual vital tissue (RVT) could be assessed in 188 of 195 lesions in 96 of 97 patients by histological examination of the explanted livers using hematoxylin and eosin (H&E) and Tdt-mediated UTP nick-end labeling (TUNEL) stains. Histopathological results were compared with the findings of the last computed tomography (CT) imaging before liver transplantation (LT). Median number and size of treated tumors were 1 (range, 1-8) and 2.5 cm (range, 1-8). Complete radiological response was achieved in 186 of 188 nodules (98.9%) and 94 of 96 patients (97.9%) and complete pathological response in the explanted liver specimen in 183 of 188 nodules (97.3%) and 91 of 96 patients (94.8%), respectively. In lesions ≥3 cm, complete tumor cell death was achieved in 50 of 52 nodules (96.2%). Residual tumor did not correlate with tumor size (P = 0.5). Conclusion: Multiprobe SRFA with intraprocedural image fusion represents an efficient, minimally invasive therapy for HCC, even with tumor sizes larger than 3 cm, and without the need of a combination with additional treatments. The results seem to justify the additional efforts related to the stereotactic approach.
引用
- Bale R, Schullian P, Eberle G, et al. Stereotactic Radiofrequency Ablation of Hepatocellular Carcinoma: a Histopathological Study in Explanted Livers. Hepatology. 2019. PMID: 30520063. doi:10.1002/hep.30406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。